Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Holdings Inc. is projected to experience significant growth, with WAKIX sales expected to rise from approximately $160 million in 2020 to over $700 million by 2024, driven by its safety and convenience advantages. The company is well-positioned for further expansion through its robust orphan drug pipeline, which includes promising candidates for various neurological conditions, potentially leading to new drug applications and market differentiation. Additionally, the positive results from the dosing optimization study for pitolisant-GR indicate improved patient adherence due to the elimination of dose titration, thereby enhancing long-term value and potentially extending market exclusivity through 2044.

Bears say

The financial outlook for Harmony Biosciences Holdings Inc. appears negative due to several key risks that may hinder revenue growth from its primary product, WAKIX. The potential entry of new competitors and earlier-than-expected competition from generic versions of pitolisant could significantly impact market share and pricing power. Additionally, the uncertainty surrounding the success of ongoing clinical trials for various drug candidates raises concerns about the company's ability to expand its product line and address unmet medical needs, further complicating its growth prospects.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.